Last Updated : November 29, 2012
The Canadian Agency for Drugs and Technologies in Health (CADTH) has examined the comparative efficacy and safety of drug therapies for relapsing-remitting multiple sclerosis (RRMS).
The review included drugs that are currently available in Canada, and those that are newly emerging and not yet approved in Canada.
The project comprised several key components:
The impending entry of new oral and injectable agents for the treatment of RRMS will have a significant impact on evolving treatment strategies. By reviewing the evidence and developing reports and tools, CADTH is providing health care decision-makers with the evidence-based resources they need to make informed decisions.
The Canadian Agency for Drugs and Technologies in Health is piloting the inclusion of patient group input in its process for the therapeutic review of drug therapies for relapsing-remitting multiple sclerosis (RRMS).
The submitted patient group input identifies health outcomes and issues of importance to patients, and their unmet needs in managing RRMS. The patient input is systematically incorporated into this therapeutic review, beginning with informing the project protocol through to informing the Canadian Drug Expert Committee in making its recommendation(s) based on this therapeutic review.
Below is a link to the patient group input that was submitted for this project. It has not been summarized, edited, or critically appraised — it is posted in the format in which it was received.
CADTH's work on this project resulted in the following key messages: